stoxline Quote Chart Rank Option Currency Glossary
  
Panbela Therapeutics, Inc. (PBLA)
0.34  -0.01 (-2.86%)    07-18 13:25
Open: 0.3699
High: 0.3699
Volume: 4,000
  
Pre. Close: 0.35
Low: 0.34
Market Cap: 2(M)
Technical analysis
2024-07-18 4:53:40 PM
Short term     
Mid term     
Targets 6-month :  0.47 1-year :  0.55
Resists First :  0.41 Second :  0.47
Pivot price 0.36
Supports First :  0.3 Second :  0.24
MAs MA(5) :  0.34 MA(20) :  0.36
MA(100) :  0.55 MA(250) :  11.5
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  39.3 D(3) :  41.3
RSI RSI(14): 44.3
52-week High :  61.4 Low :  0.3
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PBLA ] has closed above bottom band by 16.4%. Bollinger Bands are 86.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 107 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.37 - 0.37 0.37 - 0.38
Low: 0.33 - 0.34 0.34 - 0.34
Close: 0.34 - 0.34 0.34 - 0.34
Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Headline News

Tue, 16 Jul 2024
Panbela Therapeutics (NASDAQ:PBLA) Trading Up 2.3% - American Banking and Market News

Mon, 24 Jun 2024
Panbela Therapeutics Announces Third Independent Safety - GlobeNewswire

Thu, 16 May 2024
Panbela Therapeutics at Risk: Penny Stock Classification May Weaken Legal Safeguards and Hurt Valuation - TipRanks

Wed, 15 May 2024
Panbela Provides Business Update and Reports Q1 2024 Financial Results - Yahoo Finance

Tue, 26 Mar 2024
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript - Seeking Alpha

Thu, 07 Mar 2024
Nasdaq to delist Panbela Therapeutics over equity shortfall - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 5 (M)
Shares Float 5 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 107 (K)
Shares Short P.Month 46 (K)
Stock Financials
EPS 73.95
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.67
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -127.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -25 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.52
Price to Sales 0
Price to Cash Flow -0.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android